| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Fran Schulz is Director at FOCL. Fran Schulz's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $62K at current prices.
Net of sales, the FOCL filings show accumulation of 10,000 shares.
Fran Schulz has 4 Form 4 filings on record from December 2024 to August 2026, across 2 companies: Director at Edap Tms (FOCL), 2026; Director at Senti Biosciences (SNTI), 2024–2025.
The 4 reported transactions were 3 option or other derivative awards and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $48K and no sales.
The only open-market purchase was 10,000 shares of FOCL at an average $4.75 on August 14, 2026, about $48K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | FOCL Edap Tms S.A. | Director | Buy | 10,000 | $4.75 | $47,500.00 | +196.1% |